Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Discover how Semaglutide helped me lose 120 pounds and transform my life. A personal, honest look at the ups, downs, and what really worked.

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

In this cohort study, the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) semaglutide and tirzepatide was associated with a lower risk of dementia, stroke, and all-cause mortality in ...